Substance / Medication

Eribulin

Overview

Active Ingredient
eribulin
RxNorm CUI
1045453

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
5
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.
Zhang Jialin, Su Jingyang, Ni Cui et al. · Future Oncol · 2024
PMID: 39563608Meta-AnalysisFull text (PMC)
Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.
Tanni Kaniz Afroz, Truong Cong Bang, Johnson Brandon S et al. · Crit Rev Oncol Hematol · 2021
PMID: 34087344Meta-Analysis
Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot Isabelle, Zhao Qi, Su Yun · Curr Med Res Opin · 2020
PMID: 33044090Meta-Analysis
Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients.
Brems-Eskildsen Anne Sofie, Kristoffersen Kristina Bak, Linnet Søren et al. · Acta Oncol · 2019
PMID: 30101626Meta-Analysis
Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
Garrone Ornella, Miraglio Emanuela, Vandone Anna Maria et al. · Future Oncol · 2017
PMID: 29219017Meta-Analysis
A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer.
Voutsadakis Ioannis A · Anticancer Drugs · 2017
PMID: 28263201Meta-Analysis
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study.
Narui Kazutaka, Miura Daishu, Hasegawa Yoshie et al. · Clin Breast Cancer · 2022
PMID: 36151017RCT
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Spira Alexander I, Iannotti Nicholas O, Savin Michael A et al. · Clin Lung Cancer · 2012
PMID: 21862415RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eribulin (substance)
SNOMED CT
708166000
UMLS CUI
C2350866
RxNorm CUI
1045453

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.